Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.
-
Upload
jessie-webster -
Category
Documents
-
view
219 -
download
1
Transcript of Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.
![Page 1: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/1.jpg)
Wafaa El-Sadr, MD, MPHICAP-Columbia University
The World Before SMART
![Page 2: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/2.jpg)
Think Back
![Page 3: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/3.jpg)
HIV eradication
“...2.3 - 3.1 years of a completely inhibitory treatment would be required to eradicate HIV completely.”
![Page 4: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/4.jpg)
HIV-Associated Lipodystrophy
New England Journal of Medicine (1998:339;1296). International Journal of STD and AIDS (1198;9:596).
![Page 5: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/5.jpg)
Myocardial Infarction and ART Exposure
012345678
None <1 1-2 2-3 3-4 >4
MIs per 1,000 PY (95% CI)
No. MIs
No. PY3 9 14 22 31 47
5,714 4,140 4,801 5,847 7,220 8,477
Years on CART Total
126
36,199
Test for trendp<0.00001
D:A:D, NEJM, 2003
![Page 6: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/6.jpg)
Why Treatment Interruption?
• Lifelong use of ART inevitable in absence of cure• Risk of complications low at lower CD4+ cell counts• Adverse events from ART• Serious complications e.g. CVD, hepatic and renal• Difficulty in maintaining high rates of adherence• HIV resistance likely with prolonged ART• Pill-taking onerous and may be associated with
decrease in quality of life• Cost of ART is substantial, particularly in resource-
limited countries
![Page 7: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/7.jpg)
The Story of SMARTThe Beginning
• April 8, 2000 - Meeting in New York City• Who: Cal Cohen, Wafaa El-Sadr, Fred
Gordin, Birgit Grund, Carlton Hogan, Jim Neaton, Claire Rappaport, Debby Wentworth
• Where: 535 West 110th Street, Apt 14H• Outcome: Outline of the SMART design
Study name identified
![Page 8: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/8.jpg)
SMART--The Beginning
![Page 9: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/9.jpg)
9
The SMART Study Question
What is the optimal way to use ART?
![Page 10: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/10.jpg)
Weighing Pros and Cons
DCVS
![Page 11: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/11.jpg)
SMART Study Design
Drug Conservation (DC) Strategy
[Stop or defer ART until CD4+ < 250; then episodic ART based on
CD4+ cell count to increase counts to > 350]
Virologic Suppression (VS) Strategy
[Use of ART to maintain viral load as low as possible throughout
follow-up]
CD4+ cell count >350 cells/mm3
n = 3000 n = 3000
Plan: 910 primary endpoints, 8 years average follow-up
![Page 12: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/12.jpg)
Primary Endpoint
• HIV clinical disease progression or death
Other Key Endpoints
• Death• Serious HIV progression events• Severe complications: cardiovascular, renal and hepatic
![Page 13: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/13.jpg)
13
SMART Study
CPCRARCC
SydneyRCC
CopenhagenRCC
LondonRCC
BrazilCanadaPeruUnited States
ArgentinaAustraliaJapanNew Zealand
AustriaBelgiumDenmarkFinlandGermanyNorwayPolandPortugalSpain
France
Greece
Ireland
Italy
Morocco
Switzerland
United Kingdom
![Page 14: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/14.jpg)
Baseline Characteristics
North America
Europe
South America
Australia/NZ
Asia
Africa
57%
26%
10%
3%3% 1% Countries: 33
Sites: 318
Total enrollment: 5472
Age: 46 yearsWomen: 27%Blacks: 30%
![Page 15: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/15.jpg)
SMART MeetingJanuary 2006
![Page 16: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/16.jpg)
![Page 17: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/17.jpg)
International HIV/AIDS Trial Finds Continuous Antiretroviral Therapy Superior to Episodic Therapy The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today announced that enrollment into a large international HIV/AIDS trial comparing continuous antiretroviral therapy with episodic drug treatment guided by levels of CD4+ cells has been stopped. Enrollment was stopped because those patients receiving episodic therapy had twice the risk of disease progression (the development of clinical AIDS or death), the major outcome of the study.
FOR IMMEDIATE RELEASEWednesday, Jan. 29, 2006 Media Contact:Laurie K. Doepel(301) [email protected]
![Page 18: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/18.jpg)
![Page 19: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/19.jpg)
SMART Primary Outcome
SMART, NEJM 2006
![Page 20: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/20.jpg)
SMART-Non-AIDS Events
SMART, NEJM 2006
![Page 21: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/21.jpg)
Definitive Evidence from SMART- Treatment Interruption
Before SMART results After SMART results
2003 2004 2005 2006 2007 2008 2009
Number 1239 1405 1578 1690 1807 1943 2064
Number interrupting ART regimen
66 (5.3%)
95 (6.8%)
98 (6.2%)
84 (5.0%)
70 (3.9%)
64 (3.3%)
55 (2.7%)
Person-years in ART-experienced individuals
1535.41 1712.9 1840.82 1955.09 2071.98 2192.71 2254.07
Person-years spent on ART during year
1351.36 (88.0%)
1529.64 (89.3%)
1663.4 (90.4%)
1799.91 (92.1%)
1922.94 (92.8%)
2071.02 (94.5%)
2167.85 (96.2%)
Smith, Phillips et al
![Page 22: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/22.jpg)
Reasons for ART Interruption Before SMART results After SMART results
2003 2004 2005 2006 2007 2008 2009
Number interrupted ART 66 95 98 84 70 64 55
Reason for stopping
Patient choice (without adverse events)
39 (59.1%)
62 (65.3%)
71 (72.5%)
61 (72.6%)
56 (80.0%)
52 (81.3%)
44 (80.0%)
Treatment failure (VL, CD4 or resistance)
9 (13.6%)
15 (15.8%)
5 (5.1%)
2 (2.4%)
1 (1.5%)
0 (0.0%)
0 (0.0%)
Poor compliance 5 (7.6%)
5 (5.3%)
2 (2.0%)
1 (1.2%)
3 (4.3%)
1 (1.6%)
2 (3.6%)
Toxicity (any)A 9 (13.6%)
13 (13.7%)
9 (9.2%)
13 (15.5%)
6 (8.6%)
5 (7.8%)
3 (5.5%)
Smith, Phillips et al
![Page 23: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/23.jpg)
Paradigm ShiftPathogenesis of HIV Disease
![Page 24: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/24.jpg)
A New Paradigm
Time in YearsInfection
CD4+
cel
ls C
ount
1000
800
600
400
200
0
Opportunistic Diseases
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Ongoing Morbidity from HIV
![Page 25: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/25.jpg)
Conclusions
• SMART challenged the status quo • Seeking definitive answers to tough questions is
not easy, requires patience, may be costly, but is well worth it
• Getting an unexpected answer to a question is often more profound than getting the expected answer
• Other tough questions of the hour remain, and will require similar efforts to answer them
![Page 26: Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649e2c5503460f94b1c072/html5/thumbnails/26.jpg)
SMART - A Paradigm ShiftSTART - Another One?